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Proliferative diabetic retinopathy is characterized by pathological retinal neovascularization, mediated by both angiogenesis
(involving mature endothelial cells) and vasculogenesis (involving bone marrow-derived circulating endothelial progenitor
cells (EPCs)). Pigment epithelium-derived factor (PEDF) contains an N-terminal 34-amino acid peptide (PEDF-34) that has
antiangiogenic properties. Herein, we present a novel ﬁnding that PEDF-34 also possesses antivasculogenic activity. In the oxygen-
induced retinopathy (OIR) model using transgenic mice that have Tie2 promoter-driven GFP expression, we quantiﬁed Tie2GFP+
cells in bone marrow and peripheral blood by ﬂuorescence-activated cell sorting (FACS). OIR signiﬁcantly increased the number
of circulating Tie2-GFP+ at P16, correlating with the peak progression of neovascularization. Daily intraperitoneal injections of
PEDF-34 into OIR mice decreased the number of Tie2-GFP+ cells in the circulation at P16 by 65% but did not aﬀect the number
of Tie2-GFP+ cells in the bone marrow. These studies suggest that PEDF-34 attenuates EPC mobilization from the bone marrow
into the blood circulation during retinal neovascularization.
1.Introduction
Vascular development is regulated by a tight and complex
balance between pro- and anti-angiogenic factors such as
vascular endothelial growth factor (VEGF) and pigment
epithelium-derived factor (PEDF), respectively [1–4]. This
balance is important to maintain homeostasis of blood
vessel formation. Under certain pathological conditions,
such as proliferative diabetic retinopathy, age-related mac-
ular degeneration, tumorigenesis, and rheumatoid arthritis,
this balance is disrupted, leading to pathological neovas-
cularization [1, 3]. Pathological neovascularization involves
two distinct mechanisms, vasculogenesis, in which bone
marrow-derived endothelial progenitor cells (EPCs) con-
t r i b u t et on e wb l o o dv e s s e lf o r m a t i o n[ 5–8], and angiogen-
esis, in which existing mature endothelial cells proliferate
and migrate to form new blood vessels [9, 10]. Several
angiogenic inhibitors have been identiﬁed which eﬀectively
inhibit pathological neovascularization, but the eﬀect of
such antiangiogenic factors on vasculogenesis has not been
established.
PEDF is a 50-kDa secreted glycoprotein bearing mul-
tiple biological activities [11–15], including potent anti-
angiogenic activity, which has been shown to inhibit patho-
logical neovascularization, such as retinal neovasculariza-
tion, which occurs during proliferative diabetic retinopathy
[12, 14, 15]. However, the eﬀect of PEDF on vasculogenesis
has not been documented. Recently, a 34-amino acid peptide
derived from the N-terminus of PEDF (PEDF-34) was found
to possess intact ex vivo antiangiogenic activity and inhibit
choroidal neovascularization in rats [16, 17]. In the present
study, we investigated the direct eﬀects of PEDF-34 on
the proliferation and viability of primary endothelial cell
cultures and on in vivo blood vessel development using the
chicken chorioallantoic membrane (CAM) assay. We also
used the oxygen-induced retinopathy (OIR) mouse model to2 Experimental Diabetes Research
assess the ability of the PEDF-34 to inhibit retinal neovascu-
larization. Using transgenic mice that express GFP under the
control of the endothelial cell-lineage speciﬁc promoter Tie2
(Tie2-GFP mice), we quantiﬁed bone marrow-derived EPCs
and circulating endothelial cells by ﬂuorescence-activated
cell sorting (FACS) of Tie2-GFP+ cells. These studies are the
ﬁrsttodemonstratethatsystemicadministrationofPEDF-34
peptide is suﬃcient to inhibit retinal neovascularization. We
also demonstrate for the ﬁrst time that retinal neovascular-
ization in the OIR model coincides with a spike in the num-
ber of circulating endothelial cells and EPCs. Furthermore,
PEDF-34 blocks the spike in circulating endothelial cells and
EPCs during OIR. These data suggest that in addition to
its localized anti-angiogenic eﬀects on neovascular lesions,
PEDF may also have a systemic activity that blocks the
release of EPCs from bone marrow to reduce EPC-mediated
vasculogenesis during retinal neovascularization.
2.MaterialsandMethods
2.1. PEDF-34 Peptide. The PEDF-34 peptide, spanning from
amino acids 44 to 77 of the N-terminus of the PEDF protein,
was chemically synthesized by Proteintech lab (Chicago, IL)
and puriﬁed by HPLC. Proper synthesis of the peptide was
controlled by mass spectrometry.
2.2. Bovine Retinal Capillary Endothelial Cell (BRCEC)
Isolation and Culture. BRCEC were isolated from whole
retinas of cows younger than 18 months in accordance
with USDA regulations. Brieﬂy, retinas were carefully
singled out from eyecups, washed, homogenized, and
digested prior to being applied to a series of ﬁlters. Cells
were grown in collagen-coated ﬂask in the presence of
10% human serum in Dulbecco’s modiﬁed eagle medium
(DMEM) containing low glucose (1g/L) until conﬂuency.
The endothelial cell identity of the BRCEC cultures was
conﬁrmed by their ability to uptake acetylated low-density
lipoprotein (LDL) labeled with 1,1 -dioctadecyl-3,3,3 ,3 -
tetramethylindocarbocyanine (Dil-Ac-LDL) (Harbor Bio-
Products). Following a 1hr incubation with Dil-Ac-LDL,
cells were ﬁxed in 4% paraformaldehyde, counterstained
with DAPI included in mounting media (Vectorlabs,
Burlingame), and examined by ﬂuorescence microscopy.
Only BRCEC preparations with more than 95% purity were
used in this study.
2.3. Cell Viability Assays. Ac e l ll i n ed e r i v e df r o mr a t
M¨ uller cells, rMC-1, was kindly provided by Dr. Sarthy at
Northwestern University. BRCECs between passages 3 and
8 were seeded in gelatin-coated 48 well plates. BRCECs
and rMC-1 cells were maintained in regular DMEM growth
media until the assay. Then, the growth media were replaced
with DMEM containing 1% FBS, low glucose (1g/L), and
1% antibiotic/antimycotic, and the cells were treated with
PEDF-34invariousconcentrationsfor72h.Attheendofthe
treatment, an MTT assay (Roche, Nonnenwald Germany)
was performed according to the manufacturer’s recommen-
dation. Data were collected on a Victor plate reader.
2.4. Detection of Apoptosis by FACS Analysis. Adherent
BRCECs were trypsinized for 2min, and the trypsiniza-
tion was stopped with PBS/10% fetal calf serum. Then
cells were washed twice with annexin-binding buﬀer and
incubated with 2.5μL annexin-PE and 2.5μL 7AAD for
20min according to the instructions of the manufacturer
(Pharmingen, Annexin V-Pe Apoptosis Kit). The cells were
analyzed by ﬂuorescence-activated cell sorting (FACS) using
a FACSCalibur ﬂow cytometer and Cell Quest software (BD
Biosciences, Rockville, MD).
2.5.ChickenChorioallantoicMembrane(CAM)Assays. CAM
assays were used to assess the antiangiogenic potential of
PEDF-34 in vivo. Brieﬂy, fertilized eggs were incubated at
37◦Cand65%relativehumidityforthreedayswitharocking
mechanism. The embryos were then removed from the
incubator, washed with a 1:100 solution of benzalkonium
chloride (Research Chemicals, Heyshan Lanes, UK) in
distilled water, and cracked out into 100-mm Petri dishes
(BD Falcon, Franklin Lakes, NJ). A circular section (1.2mm
diameter) of nitrocellulose was saturated with either PEDF-
34 or control peptide at the required concentration. An
identical nitrocellulose section was saturated with sterile PBS
and used as internal control in each CAM. The nitrocellulose
diskswereplacedontothesurfaceoftheembryoinanareaof
activevascularization.EachpeptideandthecontrolPBSwere
reappliedontothedisksevery24h.After72hincubation,the
disks were carefully removed from the surface of the embryo.
Images were taken of the area in the vicinity of the removed
disks. Blood vessel density was evaluated by densitometric
analysis of the images of the disk areas using ImageJ (NIH).
2.6. Induction of Retinal Neovascularization in Mice and
Quantiﬁcation of Retinal Nuclei. Tie2-GFP mice, transgenic
mice that express GFP under the control of the Tie-
2 promoter were a kind gift from Dr. Sanai Sato. The
Tie2-GFP mice at postnatal day 7 (P7) were exposed to
hyperoxia (75% O2)f o r5d a y s .T h e yw e r eb r o u g h tb a c kt o
normoxic room air at P12 and were thereafter maintained
at normoxia to induce retinal neovascularization. At P12
the OIR mice were separated into 2 groups: one group
was injected intraperitoneally with PEDF-34, once a day
from P12 to P17, and the other group was injected with
BSA in a similar fashion. At P18, the eyes were enucleated,
ﬁxed in 10% paraformaldehyde, and embedded in paraﬃn.
Sagittal sections of 5μm thickness were made using a
microtome (Microm HM 325). Noncontinuous sections
were mounted on slides and stained with hematoxylin and
eosin as described by Smith et al. [18]. Light microscopy
was used to count nuclei of vascular cells present on the
vitreal side of the retina. A total of 8 sagittal sections from
each eye were examined, and cell numbers were averaged
for each group. The average number of preretinal nuclei was
compared to the control group by Student’s t-test.
2.7. EPC Isolation. Tie2-GFP mice in FVB background were
used in this study. For bone marrow cell isolation, tibias
were collected, extensively ﬂushed with PBS and crushed.Experimental Diabetes Research 3
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Figure 1: PEDF-34 acts in a concentration-dependent manner to inhibit cell proliferation and induce apoptosis speciﬁcally in endothelial
cells. (a) The purity of primary BRCEC was examined using Dil-Ac-LDL uptake assays. The cells were counter-stained with DAPI, and
exhibited a >99% purity based on positive Dil-Ac-LDL uptake. Both rat M¨ uller cells (b) and BRCEC (c) were treated with increasing
concentrations of PEDF 34-mer ranging from 25 to 400nM. Viable cells were quantiﬁed after 72h by MTT assay and expressed as % of
the cells in control treated with the BSA only (denoted as NT on graph). (d) BRCECs were treated with increasing concentrations of PEDF
34-mer for 24h. Apoptotic cells were quantiﬁed by counting Annexin V positive cells using FACS and expressed as % in total cells (mean +
SD, n = 3).
Bone fragments and cells in suspension were applied to a
100μM ﬁler and washed with 30mL of ice-cold PBS. Cells
which passed through the ﬁlter were centrifuged for 10min
at 1,500rpm, and the supernatant was discarded. Cells were
resuspended in 4% paraformaldehyde and placed on ice
shielded from the light. For peripheral blood cell isolation,
bloodwascollectedbycardiacpunctureoftherightventricle,
transferredtoatubewithheparinsalt,andplacedonice.The
blood was then layered onto a histopaque 1083 (Sigma, Saint
Louis, MO) and centrifuged for 30min at 3000rpm. The
mononuclear cell fraction was collected and rinsed with ice-
cold PBS. Cells were resuspended in 4% paraformaldehyde
and placed on ice shielded from the light.
2.8. FACS Analysis of Tie2-GFP+ Cells. Cell were ﬁxed for
1h in 4% paraformaldehyde, and then washed three times
in cold PBS. The ﬁxed cells were applied to a FACSCalibur
ﬂow cytometer and analyzed using Cell Quest software (BD
Biosciences) using a 530nm ﬁlter. In each sample, 1,000,000
events and 30,000 events were counted for bone marrow and
circulating mononucleated cells, respectively. Collected data
was analyzed by FlowJo software (Tree Star, Ashland, OR,
USA).
2.9. Immunostaining and Confocal Microscopy of Tie2-GFP+
Cells. Tie2-GFP+ sorted cells were washed in PBS and
adhered to charged histology slides for immunostaining.4 Experimental Diabetes Research
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Figure 2: Antiangiogenic activity of PEDF 34-mer during in vivo blood vessel formation. CAMs were separately treated with either 50 or
100nM PEDF-34. (a) Left: close-up image of a chicken embryo CAM with a nitrocellulose disk containing PEDF-34 (100nM). Middle: the
disk area after removal of PEDF-34 nitrocellulose disk. Right: image of a PBS-treated-nitrocellulose control area on the same CAM with
the disk removed. Note considerable reduction in the overall number of small newly formed blood vessels, when compared with the PBS-
treated control. (b) Blood vessel density in the CAMs was assessed by software analysis. Vascular densities in the disk areas of CAMs treated
with 50 and 100nM were quantiﬁed and averaged. The graph represents the percent of vascular density found under PEDF-34-treated areas
compared to the PBS-treated control area, which was set at 100%. Vascular density in the CAM treated with PEDF-34 is signiﬁcantly lower
than the control (mean + SD, n = 5).
Cells were preincubated with the appropriate antibody
isotype to prevent nonspeciﬁc binding of the primary
antibody.Wethenusedthefollowingantibodies:anti-CD117
labeled with allophycocyanin (APC) (BD Pharmingen) and
rat antimouse CD133 (Chemicon). For CD133, we used an
antirat IgG secondary antibody labeled with Alexa 648 (BD
Pharmigen). All slides were mounted in Vectorlabs-DAPI.
The cells were imaged and analyzed on a Nikon TE2000-E.
3. Results
3.1. PEDF-34 Inhibits Cell Proliferation and Induces Apoptosis
in BRCEC. Full-length PEDF protein is known to target
endothelialcellstoinhibitproliferationandinduceapoptosis
[12], and PEDF-34 has previously been shown to inhibit
blood vessel sprouting ex vivo and inhibit the progression
of laser-induced choroidal neovascularization in rats [16].
To evaluate the direct and endothelial cell-speciﬁc eﬀects
of the PEDF-34 on cell proliferation and viability, both
BRCEC and rMC-1 cells were treated with increasing con-
centrations of PEDF-34. Beforehand, the identity and purity
of primary BRCEC cultures were conﬁrmed by evaluating
cellular uptake of ﬂuorescently-labeled acetylated LDL (Dil-
Ac-LDL), which is exclusively taken up by endothelial
cells which express the LDL receptor. More than 99% of
the isolated BRCEC were positive for Dil-Ac-LDL uptake
(Figure 1(a)). MTT cell proliferation assays showed that
r M C - 1c e l lp r o l i f e r a t i o nw a su n a ﬀected by up to 400nM of
PEDF-34 (Figure 1(b)). In contrast, the PEDF-34 inhibited
BRCEC proliferation in a concentration-dependent manner,
withaslowas50nMcausinga20%decreaseincellprolifera-
tion and with 400nM reducing cell proliferation by more
than 30% (Figure 1(c)). These data show that PEDF-34
selectively inhibits cell proliferation in endothelial cells.
To determine whether the PEDF-34 induces apoptosis in
BRCEC, Annexin V staining and subsequent FACS analysis
was used to quantify apoptotic cells. PEDF-34 increased the
percentage of apoptotic cells in a concentration-dependent
manner (Figure 1(d)), providing the ﬁrst evidence ofExperimental Diabetes Research 5
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Figure 3:SystemicinjectionofPEDF-34reducedischemia-induced
retinal neovascularization. The graph represents the average num-
ber of preretinal (vitreous) vascular cells in OIR mice treated with
BSA or PEDF-34. (mean ± SEM, BSA n = 4. PEDF-34 n = 5).
the direct and speciﬁc proapoptotic activity of the PEDF-34
in primary endothelial cells.
3.2. Locally Delivered PEDF-34 Inhibits New Blood Vessel
F o r m a t i o nI nV i v o .The chorioallantoic membrane (CAM)
of a growing chicken egg was used as a model system to
test the eﬀects of PEDF-34 on in vivo blood vessel formation
[19]. CAMs were treated with small disks of nitrocellulose
saturated with PEDF-34. Nitrocellulose saturated with PBS
alone was included in every CAM as an internal negative
control. After 72h of treatment, the areas of CAMs covered
by disks containing PEDF-34 showed fewer blood vessels
compared to the areas covered by disks containing PBS alone
(Figure 2(a)). The vessel density in the area covered by the
disk was quantiﬁed by computer analysis of digital images
and averaged. The results showed that 50nM of PEDF-34
decreased vessel density by up to 20%, and 100 nM PEDF-
34 decreased vessel density by 45%, compared to the average
vascular density of the control (Figure 2(b)), suggesting a
dose-dependent inhibitory eﬀect of PEDF-34 on in vivo
blood vessel formation.
3.3. Systemic Administration of PEDF-34 Inhibits Pathological
Retinal Neovascularization in the OIR Model. To evaluate
the eﬀects of PEDF-34 on vasculogenesis during pathogenic
neovascularization, we used the OIR mouse model, which
initiatesthepathogenesisofretinalneovascularizationbegin-
ning at P12 [18]. OIR mice received daily intraperitoneal
injections of either PEDF-34 (5mg/kg of body weight) or
the same amount of BSA as control from age P12 to P17.
At P18, neovascularization was quantiﬁed by counting pre-
retinal nuclei in 8 discontinuous sections per eye (Figure 3).
The mean preretinal neovascular cell number in the BSA
treated group was 136 ± 50 (mean ± SD, n = 4) per section.
Systemic treatment with PEDF-34 reduced the number of
preretinal neovascular cells by approximately 50% to only
64 ± 13 (mean ± SD, n = 5) per section, signiﬁcantly
lower than that in the BSA-treated group (P<. 05, n = 5)
(Figure 3). These results demonstrate that systemic injection
of PEDF-34 prevented the progression of ischemia-induced
retinal neovascularization.
3.4. Isolation and Characterization of Tie2-GFP+ Cells. In
order to study circulating endothelial cells during OIR, we
used Tie2-GFP transgenic mice, which have GFP expression
exclusively in cells of endothelial cell lineage, including
mature endothelial cells and bone marrow-derived endothe-
lial progenitor cells. Prior to commencing OIR studies, we
performed preliminary analyses to detect and characterize
Tie2-GFP+ cells from bone marrow and peripheral blood.
Bone marrow cells and peripheral blood mononuclear
cells were harvested separately as described in Section 2
a n dd e p i c t e di nFigure 4(a), and then placed on ice and
shielded from direct light. Cells were then ﬁxed in 4%
paraformaldehyde and subjected to FACS to sort Tie2-GFP+
cells. Bone marrow cells collected from wild type C57bl/6
mice were used as a negative control. Cells collected from
Tie2-GFP mice exhibited a distinctly shifted population
of Tie2-GFP+ cells that was absent in cells isolated from
wild-type mice (Figures 4(b) and 4(c)). The eﬃcacy of
FACS-mediated separation of Tie2-GFP− and Tie2-GFP+
cells was evaluated by collecting the FACS-separated cell
populations and performing postanalysis using ﬂuorescence
microscopy. After staining both cell populations with DAPI,
GFP ﬂuorescence is only visible in the population of cells
identiﬁed as Tie2GFP+ by FACS analysis (Figure 4(d)).
Thus, FACS analysis is a reliable method for isolating and
quantifying Tie2GFP+ cells.
To conﬁrm the endothelial identity of FACS-isolated
Tie2-GFP+ cells, cell populations designated as Tie2-GFP−
and Tie2-GFP+ cells were placed separately into 96-well
plates for Dil-Ac-LDL uptake assays. As expected, Dil-Ac-
LDL uptake only occurred in the designated Tie2-GFP+
cells (Figure 4(e)). This conﬁrmed the endothelial identity
of Tie2-GFP+ cells and also the reliability of the FACS-based
isolation and quantiﬁcation methods.
To conﬁrm that the Tie2-GFP+ cells represent EPCs in
addition to circulating mature endothelial cells, the Tie2-
GFP+ cells were immunostained for CD117 and CD133, two
established markers of EPCs [20–23]. CD117 and CD133
immunostaining of Tie2-GFP+ cells was easily observed
(Figure 5(a)), and quantiﬁcation by FACS revealed that at
least 90% of sorted Tie2-GFP+ cells exhibited signiﬁcant
staining for CD117 (Figure 5(b)). These results show that a
signiﬁcant portion of the Tie2-GFP+ cells are EPCs.
3.5. The Number of Circulating Tie2-GFP+ Cells Correlates
with the Progression of Retinal Neovascularization in the OIR
Model. In order to characterize the correlation between
circulating endothelial cells (including both EPCs and
mature endothelial cells) and retinal neovascularization in
the OIR model, Tie-2-GFP mice were exposed to 75%
oxygen from age P7 to P12 and then returned to room air6 Experimental Diabetes Research
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Figure 4: Isolation of Tie2-GFP+ cells from bone marrow and peripheral blood in mice. (a) Isolation of bone marrow and peripheral
blood cells was performed in parallel as depicted. Washed cells were resuspended in ice-cold PBS and shielded from the light to prevent
photobleaching. (b) and (c) Flow cytometric analysis of isolated cells. Resuspended cells were subjected to FACS on an Inﬂux cell sorter.
The proﬁle obtained from Tie2-GFP mice (c) exhibited an additional population when compared to the wild-type C57BL/6 (b) (denoted in
the shaded pink box). Therefore, this exclusive population was characteristic of the Tie2-GFP+ cells. (d) Tie2-GFP− and Tie2-GFP+ cells as
identiﬁedbyFACSanalysiswerecollectedseparately,ﬁxedontoslides,counter-stainedwithDAPI,andvisualizedbyﬂuorescencemicroscopy.
Only cells identiﬁed by prior FACS analysis as Tie2-GFP+ exhibited signiﬁcant levels of green ﬂuorescence by microscopic (100x) analysis.
(e) Tie2-GFP+ cells which were isolated by FACS from Tie2-GFP mice were viable and of the endothelial cell lineage, as demonstrated by
their ability to uptake Dil-Ac-LDL. Cells sorted by FACS as Tie2-GFP− did not have the ability to uptake Dil-Ac-LDL.
to induce retinal neovascularization [18]. Tie2-GFP+ cells
from both bone marrow and peripheral blood were quan-
tiﬁed by FACS. Age-matched Tie2-GFP mice maintained
in constant room air were used as non-OIR controls. In
bone marrow, there was no signiﬁcant increase in Tie2-
GFP+ cells at P12, P16 and P20, compared to age-matched
non-OIR controls (Figures 6(a), 6(c),a n d6(e)) suggesting
the oxygen treatment does not inﬂuence the percentage of
Tie2-GFP+ cells present in the bone marrow. In contrast,
in peripheral blood, there was a signiﬁcant increase in the
number of circulating Tie2-GFP+ cells at age P16, but not
at P12 and P20, when compared to age-matched controls
(Figures 6(b), 6(d),a n d6(f)). P16 correlates with the most
aggressive stage of retinal neovascularization which occurs
from P16–P18 [18]. Thus, the peak in the number of
circulating endothelial cells coincides with the peak of reti-
nal neovascularization, which strongly suggests circulating
endothelial cells contribute to the pathogenesis of retinal
neovascularization.
3.6. PEDF-34 Blocks the Increase in Circulating Tie2-GFP+
Cells during Retinal Neovacularization in the OIR Model. To
evaluate the potential for PEDF-34 to act on circulating
endothelial cells, OIR was induced in Tie2-GFP mice, and
once mice were returned to normoxic room air at P12 to
induce retinal neovascularization, mice received daily i.p.
injectionsofPEDF-34fromP12uptoP17.ControlOIRmice
receivedanequivalentquantityofBSA.Tie2-GFP+ cells from
peripheral blood and bone marrow were quantiﬁed by FACS
at P16. The injection of PEDF-34 (5mg/kg body weight)
resulted in a 55% reduction in the number of circulating
Tie2-GFP+ cells in the peripheral blood (Figure 7), but
did not aﬀect the number of Tie2-GFP+ cells in the bone
marrow(seeSupplementalFigure 1inSupplementaryMate-
rial available online at doi: 10.1155/2012/518426). A lower
dose of PEDF-34 (1mg/kg body weight) did not result in
a signiﬁcant decrease in the number of circulating Tie2-
GFP+ cells (Figure 7). These results suggest that PEDF-34-
mediated inhibition of Tie2-GFP+ cells in circulation is both
highly speciﬁc and dose-dependent.
3.7. The Eﬀect of PEDF-34 on Circulating Tie2-GFP+ Cells Is
Not via Regulation of VEGF. The regulation of EPC release
from the bone marrow is not well understood. However,
VEGF has previously been shown to enhance pathological
neovascularization partially by increasing the release of
EPCs from bone marrow into the blood circulation [6].
Furthermore, we have previously demonstrated that PEDF
competes with VEGF for binding to VEGF receptor 2 on
endothelial cells [24], which is suggested to be a mechanism
forthe antiangiogenic activity of PEDF. Thus, to determine if
PEDF-34 reduces circulating endothelial cells during retinal
neovascularization by targeting VEGF-mediated EPC release
from bone marrow, we tested the eﬀect of PEDF-34 on
plasma VEGF levels. Tie2-GFP mice with OIR received daily
i.p. injections of PEDF-34 or BSA (5mg/kg body weight)
from P12 to P15. VEGF concentrations in the plasma were
measured by ELISA at P16. PEDF-34 did not aﬀect VEGF
plasma levels, compared to the group treated with BSA
(Supplemental Figure 2).
4. Discussion
Pathological neovascularization is a common cause of vision
loss in diabetic retinopathy. With the number of patients
aﬀected by diabetes growing rapidly, it has become a8 Experimental Diabetes Research
CD117
CD133
DAPI GFP Marker Merge
(a)
Tie2-GFP ﬂuorescence
CD117
imm
unoﬂuor
esc
enc
e
36.9
2.74 3.08
101
102
103
104
101 102 103 104
57.3
(b)
Figure 5: Characterization of circulating Tie2-GFP+ cells as EPCs. (a) Tie2-GFP+ cells from Tie2-GFP mice were sorted onto slides and
immunostained for the EPC-speciﬁc markers CD117 and CD133 and counterstained with DAPI. Confocal microscopy was used to capture
images at 40x magniﬁcation; (b) EPCs were ﬁxed, sorted for GFP, then immunostained for CD117, and subjected to FACS. Most Tie2-GFP+
cells stained positive for CD117, indicating the majority of circulating endothelial cells are EPCs.
major public health quest to arrest and prevent neovascular
complications associated with diabetes. Although several
anti-VEGF therapies have displayed beneﬁcial eﬀects for the
treatment of diabetic retinopathy, patients often become
refractive to anti-VEGF therapy. Thus, more drugs with
diﬀerent molecular mechanisms need to be developed. Vas-
culogenesis was previously considered to occur primarily
during physiological development of vasculature, but recent
evidence indicates that EPC-mediated vasculogenesis also
contributes to pathological neovascularization, including
retinal neovascularization [4, 5, 7, 20]. Thus, blockade of the
release of EPCs from the bone marrow into the circulation
represents a new target for pharmacological intervention of
pathological neovascularization.
Endogenous antiangiogenic proteins have been inten-
sively studied over the past few years due to their therapeutic
potentialinthetreatmentofneovasculardisorders,including
proliferative diabetic retinopathy [25]. Their regulatory roles
in angiogenesis have been well established in vitro and in
vivo [12, 15, 26, 27], although their eﬀects on circulating
endothelial cells and EPC-mediated vasculogenesis have not
been investigated previously. The data presented hereinExperimental Diabetes Research 9
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Figure 6: The number of circulating endothelial cells and EPCs increases in OIR mice at P16. Tie2-GFP+ cells in both the bone marrow
(BM) and peripheral blood (PB) from Tie2-GFP mice were quantiﬁed by FACS at p12, p16 and p20 under normoxic rearing conditions
(grey), or in the OIR model (black). Graphs represent the percent of Tie2-GFP+ cells based on 100% being set to the average number of
Tie2-GFP+ cells from normoxic mice.10 Experimental Diabetes Research
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Figure 7: PEDF-34 reduces the number of circulating endothelial
cells and EPCs in OIR mice. In the OIR model, Tie2-GFP pups
received a daily i.p. injection of either PEDF-34, BSA, or a control
p e p t i d ei nP B Sa tad o s eo f5m g / k go fb o d yw e i g h tf r o mP 1 2t o
P16. At P16, Tie2-GFP+ circulating endothelial cells and EPCs in
peripheralbloodwerequantiﬁedbyFACS.Thegraphrepresentsthe
percentage of Tie2-GFP+ cells in peripheral blood, based on 100%
being set to the average number of Tie2-GFP+ cells from OIR mice
injected with BSA alone.
demonstrates that a 34-amino acid peptide fragment derived
from the N-terminus of the angiogenic inhibitor PEDF
inhibits circulating endothelial cells and EPCs during the
pathogenesis of retinal neovascularization in the OIR model.
The OIR model is commonly used to study retinal
neovascularization [18], because it has a well-characterized
and highly reproducible course of retinal neovascularization.
In the OIR model, transient exposure to hyperoxia from
P7 to P11, followed by return to normoxia at P12 causes
ischemia-induced retinal neovascularization that involves
increased VEGF expression, decreased PEDF expression, and
increased vascular leakage [3, 15]. Previous studies have
shown that these features of retinal neovascularization are
transient and peak at P16–P18. The present study is the ﬁrst
to demonstrate that the number of circulating endothelial
cells and EPCs also peaks at P16 during OIR, correlating
with the peak in VEGF expression and the most aggressive
stage of retinal neovascularization. This correlation provides
strong evidence that the increase in circulating endothelial
cells and EPCs contributes to the retinal neovascularization
in the OIR model. In contrast, EPC abundance in bone
marrow is not changed in OIR mice at any of the time
points analyzed. However, it is likely that bone marrow-
derived EPCs are mobilized and contribute to the spike
in circulating endothelial cells and EPCs, and that their
numbers are so quickly replenished in the bone marrow that
no mobilization-induced dip in bone marrow EPC numbers
is observed. This theory is supported by our data which
shows that most circulating endothelial cells also express
EPC markers (Figure 5), and thus, are likely to have recently
entered the circulation from the bone marrow.
Similar to previous studies of full-length PEDF, the
systemic injections of PEDF-34 signiﬁcantly reduced the
progression of retinal neovascularization in the OIR mouse
model. Furthermore, PEDF-34 blocked the OIR-induced
spike in circulating endothelial cells at P16. This strongly
suggests that PEDF-34 inhibits retinal neovascularization by
targeting and reducing circulating endothelial cells, although
the mechanism by which PEDF-34 reduces circulating
endothelial cells and EPCs is unclear. Our ﬁnding that
PEDF-34 inhibits cell proliferation and induces apopto-
sis in primary endothelial cell culture suggests PEDF-34
may directly target circulating endothelial cells and EPCs
to induce apoptosis or inhibit cell proliferation. Another
possibility is that PEDF-34 may block the release of EPCs
from the bone marrow into the circulation. Regulation of
EPCreleaseisnotwellunderstood.However,VEGFisknown
to play an important role [6]. We measured VEGF levels in
the plasma following treatment with PEDF-34 and found
that VEGF levels in the plasma were not aﬀected by systemic
administration of PEDF-34 (Supplemental Figure 2). How-
ever, our previous studies have shown that PEDF competes
with VEGF for binding to VEGF receptor 2 (VEGFR2)
[24], which accounts for some of the antiangiogenic activity
of PEDF. Thus, it is possible that PEDF-34 could bind to
VEGFR2 on EPCs and impede VEGF signaling to reduce the
VEGF-induced stimulation of EPC release without reducing
VEGFlevels.Alternatively,PEDF-34mayprimarilytargetthe
existing vasculature and neovascular lesions to reduce the
expression of cell adhesion molecules and soluble signaling
molecules, such as α5β3 and α5β5 integrins, intercellular
adhesion molecule 1 (ICAM1), and vascular cell adhesion
molecule 1 (VCAM1), which act as recruitment signals for
circulatingendothelialcellsandEPCs.Inthiscase,thePEDF-
34-mediated reduction in circulating endothelial cells and
EPCs could be an indirect result of PEDF-34 targeting the
vasculature to decrease expression of recruitment factors.
5. Conclusion
This study is the ﬁrst to demonstrate that an antiangiogenic
peptide, PEDF-34, reduces circulating endothelial cells dur-
ing ischemia-induced neovascularization. This strongly sug-
gests that the PEDF-34 peptide combines antivasculogenic
activity and antiangiogenic activity in one peptide. Thus, the
PEDF-34 peptide could be a superior biological therapeutic
for the treatment of pathological neovascularization, such
as proliferative diabetic retinopathy. Since PEDF-34 is a
fragment from an endogenous human protein which exists
in normal human tissues, and because the small PEDF-34
peptide can be generated in large quantity with high purity
by solid phase synthesis, PEDF-34 has great potential for
large-scale pharmaceutical development.
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